ACU Q2 Earnings Beat Estimates on MyMedic Growth and Margin Expansion

• Acme United Corporation (ACU) reported second-quarter 2026 earnings per share of $1.22, beating estimates by over 50% and driving a 12% stock surge.
• Revenue reached $62.7 million, exceeding forecasts by nearly 8%, as the MyMedic acquisition and 8% organic growth propelled a 16% year-over-year sales increase.
• Gross margins expanded to 42.6% from 41.0% in the prior year period, with management citing replacement of higher-tariff inventory as a key driver.
• Investors should monitor elevated SG&A expenses at 32% of sales and uneven geographic performance, particularly in the Canadian market.

Acme United Corporation delivered a robust second-quarter 2026 performance that significantly exceeded Wall Street expectations. The company reported earnings per share of $1.22, a stark contrast to the consensus estimate of $0.81 . This 50.62% surprise prompted an immediate market reaction, with shares surging nearly 12% to reach a 52-week high near $51.88 . The positive momentum underscores investor confidence in the company's strategic execution and growth trajectory.

Top-line growth was equally impressive, with total revenue hitting $62.7 million against an expected $58.1 million . This 7.99% revenue beat was largely attributed to the acquisition of MyMedic, which contributed substantially to the 16% year-over-year sales increase . Even excluding the impact of the acquisition, the company demonstrated strong organic growth of 8% . This dual engine of acquisition-driven and organic expansion highlights the company's ability to capitalize on both strategic mergers and core operational improvements.

Profitability metrics also showed marked improvement, with gross margins expanding to 42.6% from 41.0% in the prior year period . CEO Johnsen highlighted that this margin recovery is expected to continue as the company transitions from higher-tariff inventory to lower-cost stock . This transition process is anticipated to conclude by the end of the year, further supporting margin expansion . The integration of MyMedic remains a strategic priority, with a focus on expanding distribution from direct-to-consumer channels into mass retail .

How Do Tariffs and Costs Impact ACU's Margins?

While the company is benefiting from easing tariff pressures, it continues to face several operational headwinds. Selling, general, and administrative (SG&A) expenses remain elevated at 32% of sales . These high operating expenses have been a recurring theme, particularly in the first quarter of 2026, where they outpaced gross profit growth and compressed net income margins . Investors must monitor whether the current quarter's margin expansion can be sustained despite these persistent cost pressures.

Additionally, the company faces ongoing risks related to freight costs and currency fluctuations . Geographic performance remains uneven, with the Canadian market lagging behind other regions . These factors introduce volatility that could impact future profitability, despite the strong Q2 results. The company's ability to manage these costs while integrating MyMedic will be critical for long-term margin stability.

Is ACU's Revenue Model Seasonal and What Does Q4 Look Like?

Acme United exhibits a highly seasonal revenue model, with the second quarter consistently serving as the peak period for revenue and profitability . For instance, Q2 2026 saw a 19.9% year-over-year revenue surge, resulting in a 412% increase in net income to $5.05 million . This contrasts sharply with the first quarter, where net income fell 47.5% to $0.985 million despite 10% revenue growth . The company maintains a stable dividend policy, with per-share dividends increasing to $0.16 in 2026, reflecting confidence in annual cash flows despite quarterly volatility .

Looking ahead, management projects strong profitability for the fourth quarter, citing seasonal demand patterns for MyMedic products . The integration of MyMedic into mass retail channels is expected to drive further growth in the latter half of the year . However, historical data shows significant volatility in EPS surprises, ranging from -56% to +58% over the past two years . This underscores the importance of monitoring operational drivers closely, as the company's profitability is heavily concentrated in specific quarters .

Despite the positive quarter, investors should remain cautious about the company's exposure to external factors. Tariff costs, freight expenses, and currency headwinds continue to pose risks to the bottom line . The uneven geographic performance, particularly in Canada, adds another layer of complexity to the growth story . While the MyMedic acquisition has been a significant driver of success, the company must continue to execute on its integration strategy to maintain momentum . The market's positive reaction to the Q2 results suggests optimism, but sustained growth will depend on the company's ability to navigate these ongoing challenges and capitalize on seasonal demand .